-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Inarigivir soproxil
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/942123-43-5.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 942123-43-5 |
| Description | Inarigivir soproxil is an orally active agonist of innate immunity that works via the RIG-I and NOD2 pathways. Inarigivir soproxil exhibits broad-spectrum antiviral activity against resistant HCV variants. |
Product Information
| Synonyms | GS 9992; SB 9200; SB9200; SB-9200 |
| IUPAC Name | [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxyphosphoryl]sulfanylmethyl propan-2-yl carbonate |
| Molecular Weight | 703.62 |
| Molecular Formula | C25H34N7O13PS |
| Canonical SMILES | CC(C)OC(=O)OCSP(=O)(OCC1C(CC(O1)N2C=NC3=C(N=CN=C32)N)O)OC4C(OC(C4OC)N5C=CC(=O)NC5=O)CO |
| InChI | InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1 |
| InChIKey | CJCYTUJOSMYXLE-JDLSZIHUSA-N |
| Purity | 99.55% |
| Density | 1.8±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : 80 mg/mL(113.70 mM;Need ultrasonic) H2O : 10 mg/mL(14.21 mM;ultrasonic and warming and heat to 60°C) In Vivo: 1.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 5 mg/mL (7.11 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 4 mg/mL (5.68 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CD in saline) Solubility: ≥ 4 mg/mL (5.68 mM); Clear solution 4.Add each solvent one by one:5% DMSO >> 40%PEG300 >> 5%Tween-80 >> 50% saline Solubility: ≥ 2.5 mg/mL (3.55 mM); Clear solution |
| Appearance | White to off-white (Solid) |
| Storage | -20°C, stored under nitrogen * In solvent : -80°C 6 months -20°C 1 month (stored under nitrogen) |
| Complexity | 1220 |
| Exact Mass | 703.16729234 |
| Index Of Refraction | 1.732 |
| In Vitro | Inarigivir soproxil (SB 9200) is a first-in-class oral modulator of innate immunity that acts via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil is an effective inhibitor of HCV replication in cell culture. The antiviral activity of Inarigivir soproxil against HCV was assessed using genotype 1 HCV replicon systems in duplicate experiments using 4 drug concentrations. Inarigivir soproxil inhibits HCV replication with EC50s of 2.2 and 1.0 µM, and EC90s of 8.0 and 6.0 µM for genotype 1A and 1B, respectively. Inarigivir soproxil (SB 9200), an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense. |
| Target | HCV; HBV |
| XLogP3-AA | -1.8 |
